Table 3. Current clinical indications for MMAE according to disease stage (de novo vs. recurrent) and clinical severity.
| Clinical severity | De novo CSDH | Recurrent CSDH |
|---|---|---|
| Severe (emergent) | Surgery is first-line (adjunct MMAE may be considered electively after stabilization; evidence is limited) |
|
| Symptomatic | Adjunct MMAE is reasonable in selected high-recurrence–risk patients | Adjunct MMAE should be considered |
| Mild symptomatic | Stand-alone MMAE can be considered | |
| Asymptomatic | Conservative management is first-line (consider MMAE if large/progressive) | |
| Not a surgical candidate/surgery contraindicated | Consider stand-alone MMAE | |
CSDH, chronic subdural hematoma; MMAE, middle meningeal artery embolization